Biogen (BIIB)
(Delayed Data from NSDQ)
$224.94 USD
+4.87 (2.21%)
Updated May 31, 2024 04:00 PM ET
After-Market: $224.85 -0.09 (-0.04%) 7:56 PM ET
3-Hold of 5 3
C Value B Growth C Momentum B VGM
Brokerage Reports
0 items in cart
Biogen Inc. [BIIB]
Reports for Purchase
Showing records 681 - 700 ( 803 total )
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Industry Report ; PHARMA & BIOTECH; This report contains brief updates on the following: VRX, PFE, NVO, MNTA, CORT, BIIB, AMGN. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: ZACKS INVESTMENT RESEARCH
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Using BAN2401?s Trial Simulations to Inform Probability for Early Success and Dose Scenarios
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
A Closer Look at Eisai/BIIB?s BAN2401 Bayesian Adaptive Phase 2 Design
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
2016 Healthcare Sector Outlook: Year Ahead Perspectives
Provider: H.C. Wainwright & Co., Inc.
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
How to De-Risk Neurodegeneration: A Lesson from Biogen?s Approach to R+D
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A